uniQure Gelecekteki Büyüme

Future kriter kontrolleri 2/6

uniQure kazanç ve gelirinin sırasıyla yıllık 26.4% ve 36.8% oranında artması tahmin edilirken, EPS'nin yıllık 30.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

26.4%

Kazanç büyüme oranı

30.6%

EPS büyüme oranı

Biotechs kazanç büyümesi27.3%
Gelir büyüme oranı36.8%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme10 Oct 2024

Gelecekteki son büyüme güncellemeleri

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:QURE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026112-114-100-11110
12/31/202565-152-130-17013
12/31/202443-202-205-17713
6/30/202428-285-111-104N/A
3/31/202419-297-135-128N/A
12/31/202316-308-153-146N/A
9/30/2023112-228-161-151N/A
6/30/2023112-187-251-239N/A
3/31/2023110-157-214-198N/A
12/31/2022106-127-163-145N/A
9/30/202261-125-154-137N/A
6/30/202262-114-149-129N/A
3/31/2022525324286304N/A
12/31/2021524330271288N/A
9/30/2021500321281298N/A
6/30/2021500303292303N/A
3/31/202138-139-154-143N/A
12/31/202038-125-144-135N/A
9/30/20206-166-132-124N/A
6/30/20205-136-120-111N/A
3/31/20206-124-114-105N/A
12/31/20197-124-105-99N/A
9/30/20196-105-96-91N/A
6/30/20198-103-93-89N/A
3/31/20199-92-86-81N/A
12/31/201811-83-80-76N/A
9/30/201812-90-81-76N/A
6/30/201811-78-76-71N/A
3/31/201813-78N/A-74N/A
12/31/201713-79N/A-64N/A
9/30/201720-67N/A-62N/A
6/30/201725-72N/A-65N/A
3/31/201724-71N/A-68N/A
12/31/201625-73N/A-72N/A
9/30/201620-76N/A-81N/A
6/30/201616-90N/A-62N/A
3/31/201614-90N/A5N/A
12/31/201511-82N/A7N/A
9/30/20158-76N/A22N/A
6/30/20156-58N/A13N/A
3/31/20155-45N/A-35N/A
12/31/20146-50N/A-37N/A
9/30/20145-41N/A-29N/A
6/30/20146-42N/A-6N/A
3/31/20146-41N/A-7N/A
12/31/20134-37N/A-6N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: QURE şirketinin gelirinin (yıllık 36.8% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: QURE şirketinin gelirinin (yıllık 36.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: QURE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin